Maotian Zhou
YOU?
Author Swipe
View article: Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease
Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease Open
Core spliceosome and related RNA-binding proteins aggregate in Alzheimer’s disease (AD) brain even in early asymptomatic stages (AsymAD) of disease. To assess the specificity of RNA-binding protein aggregation in AD, we developed a targete…
View article: Additional file 3 of Coevolution of COVID-19 research and China’s policies
Additional file 3 of Coevolution of COVID-19 research and China’s policies Open
Additional file 3: Results output from VOSviewer (version 1.6.16).
View article: A consensus proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
A consensus proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation Open
Background Our understanding of the biological changes in the brain associated with Alzheimer’s disease (AD) pathology and cognitive impairment remains incomplete. Unbiased discovery proteomic analysis of AD brain can help to increase our …
View article: Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain
Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain Open
Background The repeated failures of amyloid‐targeting therapies have underscored the need for additional biomarkers of Alzheimer’s disease (AD) that reflect its complex multi‐network dysfunction. Using a network‐based proteomic approach, w…
View article: Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease Open
Integrative proteomic analysis identifies CSF biomarker panels linked to brain-based pathophysiologies in Alzheimer’s disease.
View article: Co-evolution of COVID-19 Research and China’s Policies
Co-evolution of COVID-19 Research and China’s Policies Open
The dynamics of research are a prism that reflects interactions between science, the societal environment, and government policies. Against the backdrop of the ongoing global COVID-19 pandemic, this study explored the changes in, and devel…
View article: Additional file 1 of Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
Additional file 1 of Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease Open
Additional file 1: Table S1. Summary of replication cohort characteristics. Table S2. Clinical and immunoassay metadata for all 88 cases. Table S3. Raw PRM quantified peptide peak area before normalization. Table S4. Normalized peptide pea…
View article: Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease
Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease Open
Alzheimer’s disease (AD) features a complex web of pathological processes beyond amyloid accumulation and tau-mediated neuronal death. To meaningfully advance AD therapeutics, there is an urgent need for novel biomarkers that comprehensive…
View article: A Consensus Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation
A Consensus Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation Open
Our understanding of the biological changes in the brain associated with Alzheimer’s disease (AD) pathology and cognitive impairment remains incomplete. To increase our understanding of these changes, we analyzed dorsolateral prefrontal co…
View article: O1‐01‐01: INTEGRATIVE PROTEOMICS LINKS CEREBROSPINAL FLUID BIOMARKERS TO PATHOLOGICAL NETWORKS IN THE ALZHEIMER'S DISEASE BRAIN
O1‐01‐01: INTEGRATIVE PROTEOMICS LINKS CEREBROSPINAL FLUID BIOMARKERS TO PATHOLOGICAL NETWORKS IN THE ALZHEIMER'S DISEASE BRAIN Open
There is a need for novel biomarkers of Alzheimer's disease (AD) that broadly serve as accurate indicators of the underlying pathophysiological processes occurring throughout disease. Thus, biomarker discovery should focus on identifying n…
View article: Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain
Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain Open
Gene expression contributes to phenotypic traits and human disease. To date, comparatively less is known about regulators of protein abundance, which is also under genetic control and likely influences clinical phenotypes. However, identif…